About Aurigene
Aurigene is a Healthcare company based in Bengaluru (India) founded in 2001. It operates as a discovers and develops novel oncology therapeutics via research collaborations. It operates on a B2B and Partnerships model. The company has 479 employees. Its Indian entity Aurigene Oncology Limited reported revenue of ₹172 Cr. Aurigene offers products and services including Drug Discovery Platform and Clinical Pipeline. Its focus areas include Biotech, Oncology, Cancer Therapeutics and Drug Discovery. Similar companies include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group and 5 more; 8 of its 10 listed similar companies have raised funding.
Company details
Aurigene Oncology, founded in 2001, is a clinical stage biotech company based in Bangalore, India, focused on discovering and developing innovative therapeutics for cancer treatment. It leverages advanced science and global partnerships to build a robust pipeline of drugs. The company conducts integrated drug discovery projects and collaborates with international entities to advance oncology solutions for patients worldwide.
- Headquarters Bengaluru, India
- Employees 479
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website aurigene.com
- Social LinkedIn
- Legal Name Aurigene Oncology Limited
- Date of Incorporation 10 Aug, 2001
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹172 Cr
FY 2025 · -57% YoY
- Net Loss-₹81.49 Cr
FY 2025 · -47% margin
- EBITDA-₹80.14 Cr
FY 2025 · -47% margin
- Employee Count479
Associated legal entities of Aurigene
Aurigene is associated with 2 registered companies on The Company Check; the primary company is Aurigene Oncology Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aurigene Oncology Limited CIN U24239KA2001PLC029391 | Active | 10 Aug 2001 | Bangalore, Karnataka | ₹172 Cr | 479 | 11 | View details |
| Dr.Reddy's Laboratories Ltd Listed CIN L85195TG1984PLC004507 | Active | 24 Feb 1984 | Hyderabad, Telangana | ₹35,059 Cr | 7,985 | 16 | View details |
Products & Services of Aurigene
Aurigene offers a comprehensive portfolio of products and services, including Drug Discovery Platform and Clinical Pipeline.
Platform for developing novel cancer therapeutics through research
Pipeline of drugs in trials for oncology treatment and partnerships
Board of directors of Aurigene Oncology Limited (Aurigene)
Aurigene Oncology Limited is the primary company behind Aurigene. The boards of the 2 registered companies of Aurigene currently have 19 directors; the longest-serving is Satish Reddy Kallam, appointed in 2001. 49 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Satish Reddy Kallam DIN 00129701 | Director | 10 Aug 2001 | 25 yrs 2 mo | Aurigene Oncology Limited, Dr.Reddy's Laboratories Ltd |
| Venkateswara Prasad Gunupati DIN 00057433 | Director | 10 Aug 2001 | 25 yrs 2 mo | Aurigene Oncology Limited, Dr.Reddy's Laboratories Ltd |
| Bruce Leonard Andrews Carter DIN 02331774 | Director | 30 Mar 2015 | 11 yrs 6 mo | Aurigene Oncology Limited |
| Buggana Hariharnath DIN 00695002 | Director | 30 Mar 2015 | 11 yrs 6 mo | Aurigene Oncology Limited |
| Leo Puri DIN 01764813 | Director | 25 Oct 2018 | 7 yrs 11 mo | Dr.Reddy's Laboratories Ltd |
| Shikha Sanjaya Sharma DIN 00043265 | Director | 31 Jan 2019 | 7 yrs 8 mo | Dr.Reddy's Laboratories Ltd |
| Muralidhara Ramachandra DIN 10561973 | CEO | 01 Jul 2019 | 7 yrs 3 mo | Aurigene Oncology Limited |
| Erez Israeli DIN 08563726 | CEO | 01 Aug 2019 | 7 yrs 2 mo | Dr.Reddy's Laboratories Ltd |
| Kodumudi Pranatharthiharan Krishnan DIN 01099097 | Director | 07 Jan 2022 | 4 yrs 9 mo | Dr.Reddy's Laboratories Ltd |
| Penny Chan Wan DIN 09479493 | Director | 28 Jan 2022 | 4 yrs 8 mo | Dr.Reddy's Laboratories Ltd |
| Arun Madhavan Kumar DIN 09665138 | Director | 01 Aug 2022 | 4 yrs 2 mo | Dr.Reddy's Laboratories Ltd |
| Kumar Srinivasan DIN 09730422 | Director | 01 Oct 2022 | 4 yrs | Aurigene Oncology Limited |
| Shubhada Vivek Chiplunkar DIN 09718521 | Director | 01 Oct 2022 | 4 yrs | Aurigene Oncology Limited |
| Claudio Dr. Albrecht DIN 10109819 | Director | 10 May 2023 | 3 yrs 5 mo | Dr.Reddy's Laboratories Ltd |
| Alpna Hansraj Seth DIN 01183914 | Director | 19 Sep 2023 | 3 yrs 1 mo | Dr.Reddy's Laboratories Ltd |
| Venkata Ramana Motupalli DIN 09000585 | Director | 19 Oct 2023 | 3 yrs | Aurigene Oncology Limited |
| Sanjiv Soshil Mehta DIN 06699923 | Director | 29 Dec 2023 | 2 yrs 9 mo | Dr.Reddy's Laboratories Ltd |
| Venkatanarasimham Mannam DIN 02677423 | CFO | 01 Aug 2024 | 2 yrs 2 mo | Dr.Reddy's Laboratories Ltd |
| Srikanth Velamakanni DIN 01722758 | Additional Director | 01 Jul 2026 | 3 mo | Dr.Reddy's Laboratories Ltd |
People of Aurigene
73 people are tracked at Aurigene (12 in leadership, 6 in board & advisors, 55 in team); the tracked headcount is 479.
| Name | Role | Group |
|---|---|---|
Dinesh Chikkanna | Director Medicinal Chemistry | Leadership |
D. Syed Samiulla | Function Head | Leadership |
Siva Prasad Ganta | Head Quality Control And Analytical Research | Leadership |
Akhil Kumar | Chief Medical Officer | Leadership |
Brijesh Kumar Karnani | Chief Financial Officer | Leadership |
Sanjeev Giri | Senior Vice President and Head of Early Development | Leadership |
Veerendra Patil | Vice President and Head of Human Resources and Administration | Leadership |
Subir Dubey | Vice President, Business Development | Leadership |
Kavitha Nellore | Senior Director, Cell And Molecular Biology | Leadership |
Leena Khare | Director | Leadership |
Nanduri Srinivas | Senior Director | Leadership |
Sujatha Rajagopalan | Associate Director Business Development, Licensing & Alliance Management | Leadership |
| Independent Director | Board & advisors | |
| Independent Director | Board & advisors | |
| Independent Director | Board & advisors | |
G V Prasad | Chairman of the Board | Board & advisors |
| Director | Board & advisors | |
| Independent Director | Board & advisors | |
Chandrika I | Research Associate | Team |
Hemanth K N | Research Scientist | Team |
53 more people are available in the full profile.
Complete people profiles for Aurigene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Aurigene
Figures of Aurigene Oncology Limited, the primary company behind Aurigene, for FY 2025. Revenue was ₹172 Cr (-57% year on year). Net loss was -₹81.49 Cr (-47% margin). EBITDA was -₹80.14 Cr (-47% margin). Revenue has grown at a compounded annual rate of -18% over three years and -10% over five years.
- ₹172 CrRevenue · FY 2025 · -57% YoY
- -₹81.49 CrNet loss · -47% margin
- -₹80.14 CrEBITDA · -47% margin
- ₹188 CrPaid-up capital
- 479Employees (provident fund records)
- -18%Revenue CAGR, 3 years
- -10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Aurigene Oncology Limited are on its company page.
Detailed financial statements for Aurigene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Aurigene
Aurigene has 10 listed similar companies in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed similar companies of Aurigene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aurigene
The website of Aurigene (aurigene.com) receives about 5.5K visits a month and ranks #3,284,144 among all websites worldwide, #4,318 in Biotechnology and Pharmaceuticals.
- Monthly visits5.5K
▼ 3.9% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,284,144
among all websites
- Category rank#4,318
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit35 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Aurigene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aurigeneservices.com | 100% | 16.1K | #1,244,986 | View details | |
| biobaxy.com | 84% | 1.2K | #8,516,274 | View details | |
| biocon.com | 63% | 82.3K | #297,196 | View details | |
| omniactives.com | 49% | 12.4K | #1,844,219 | View details | |
cdsco.gov.in | cdsco.gov.in | 47% | – | #224,511 | – |
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Aurigene (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurigene
Complete news archive for Aurigene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurigene
Aurigene was founded in 2001.
Aurigene is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Aurigene has 479 employees.
The primary company behind Aurigene, Aurigene Oncology Limited, reported revenue of ₹172 Cr for FY 2025, down 57% year on year.
Aurigene Oncology, founded in 2001, is a clinical stage biotech company based in Bangalore, India, focused on discovering and developing innovative therapeutics for cancer treatment. It leverages advanced science and global partnerships to build a robust pipeline of drugs. The company conducts integrated drug discovery projects and collaborates with international entities to advance oncology solutions for patients worldwide.
Aurigene's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Aurigene offers Drug Discovery Platform and Clinical Pipeline.
Aurigene is associated with 2 legal entities: Aurigene Oncology Limited, Dr.Reddy's Laboratories Ltd.
The legal entities of Aurigene currently have 23 directors, including Bruce Leonard Andrews Carter, Brijesh Kumar Karnani, Muralidhara Ramachandra and others.